Update on dosing device in new Children’s Panadol 1-5 years suspension
GlaxoSmithKline (GSK) is disappointed with the decision made on Wednesday 17 July 2013 by the Federal Court to grant a temporary injunction over a proposed alternative syringe-based dosing device for use with the new Children’s Panadol 1-5 years suspension.
GlaxoSmithKline (GSK) is disappointed with the decision made on Wednesday 17 July 2013 by the Federal Court to grant a temporary injunction over a proposed alternative syringe-based dosing device for use with the new Children’s Panadol 1-5 years suspension.
In May this year, a temporary injunction was also granted in relation to a different syringe based dosing device.
GSK is considering its options pending the final court hearings.
These legal proceedings relate to the new Children’s Panadol 1-5 years suspension only. Children’s Panadol Baby Drops, Children’s Panadol 5-12 yrs Elixir and the new Children’s Panadol 5-12 yrs suspensions are not impacted by the proceedings.
GSK reassures our valued customers that there is no safety risk associated with new Children’s Panadol range.
GSK is using its best endeavours to ensure Childrens Panadol 1-5 years suspension product will be available to customers as soon as possible.
A healthcare professional should be consulted for advice to determine what other Children’s Panadol product may be appropriate for use if the new Children’s Panadol 1-5 yrs product is not available.
When using Panadol® ALWAYS READ THE LABEL. Use only as directed. For the temporary relief of pain and fever. Incorrect use could be harmful. Consult your healthcare professional if symptoms persist.
Panadol® is a registered trademark of the GlaxoSmithKline group of companies.
For more information about Children’s Panadol visit www.childrenspanadol.com.au
